

Leading Cancer Research, Close to Home.

2009 Annual Report



hoosier oncology group

Letter from the Chairman	3
Letter from the Executive Director	4
Our Visionary Leadership	6
New Partnerships and Collaborations	8
Acknowledgments and Accolades	11
Our Financials	12
Our Supporters	16
Our Community Reach	18

Dear Colleagues,

THIS PAST YEAR HAS BEEN A VERY EXCITING ONE FOR THE HOOSIER ONCOLOGY GROUP. We have welcomed many new sites, engaged with new research partners, and have brought on several new members to our Board. You will also notice that we have a new logo! I believe the Hoosier Oncology Group has positioned itself to be the premier research organization of its kind anywhere in the country.

As we enter into 2010, I'd like to invite everyone to join us for our 25th Anniversary Gala event in April. Very few organizations make it 25 years! We can be very proud of the work we have done, but our mission is not yet complete. We remain determined to find the better cancer therapies for tomorrow.

Thank you for your support over the years and I look forward to a wonderful 2010.

Nasser Hanna, M.D.
Chairman



Letter From The Executive Director

THIS YEAR HAS TAUGHT ME TWO THINGS, focus on people and data and we will do great things in the next 25 years just like we did in the first 25 years.

We convened in 2009 a great team of people deeply invested in the Hoosier Oncology Group's success to review the "data" on our organization and the environment we operate in. I summarize the direction that flowed from six months of planning with our outstanding staff, founders, survivors, passionate volunteers and the next generation cancer researchers poised to inherit Hoosier Oncology and continue The Legacy of quality cancer research of the highest integrity.

- 1.** Strengthen IU relationship to be able to deliver community outreach thru research site development, execute quick transition from academic-centered Phase 1 studies to Phase 2 community-centered studies, and facilitate physician education as the practice of oncology becomes increasingly complex.
- 2.** Support clinical trial working groups and develop focused support of junior faculty and fellows to strengthen their research capabilities and promote career advancement thru publication of impactful research.
- 3.** Facilitate greater engagement between community and academic research physicians and ensure a bidirectional flow of information around unmet needs and science that matters to the patient.
- 4.** Listen to our sponsors needs and develop relationships that are mutually beneficial and seek to improve how research is conducted to ever increasing standards of quality, speed, and value.

All relationships in the network have been strengthened. Hoosier Oncology is only as strong as its network, and we have added strands operationally with all major stakeholders:

Patients thru community patient advocacy programs and integrating advocates into protocol and consent review, and ultimately in better dissemination of study results. Keeping the patient at the center of our operations elevates our ability to meet the right cancer challenges.

Community sites thru adoption of clear performance standards, well-funded studies, and higher visibility within CTWG's and board representation. Community engagement makes the mission run.

Translational Researchers thru ongoing relationship building with Purdue and IU lab scientists and clinicians as evidenced in the Walther Cancer Foundation Biorepository Sample Collection Study. Personalized treatment is one step closer with these efforts.

Dedicated **Volunteer** ranks from Board to Research Advocacy thru a revitalization plan to diversify and expand our organizational leadership skills and community footprint. Meeting a mission as complex as conducting cancer research in a network of academic and community sites requires input from survivors, business leaders, community representatives in addition to outstanding oncologists.

Drug Company Sponsors thru more transparency in project start-up to publication that includes better qualifying of sites for opening, enhanced budgeting, and consistent and relevant communications on study performance, early identification of potential issues, and urgency in problem resolution. Curing cancer is too complex a mission to not have high touch relationships with your partners.

Our **Employees** thru clear performance expectations, supported development, and promotion of a culture that engages all of our network of stakeholders and actively pursues best practices. Internal metrics are trending up, from employee satisfaction to the bottom-line.

We are anxious to defeat cancer. Victory by victory, Hoosier Oncology will continue leading cancer research, close to home.



Sincerely,

Peter "Quake" Pletcher
Executive Director

“Leadership and learning are indispensable to each other.”

—John F. Kennedy

Hoosier Oncology Foundation, Inc.

Nasser Hanna, M.D., Chairman, Associate Professor at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Vice-Chair, Principal Investigator for the Northern Indiana Cancer Research Consortium, South Bend, IN

James Ruckle, Ph.D., Secretary/Treasurer, President and CEO of Walther Cancer Foundation, Indianapolis, IN

Hoosier Oncology Group, Inc.

Nasser Hanna, M.D., Chairman, Associate Professor of the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Vice-Chair, Principal Investigator for the Northern Indiana Cancer Research Consortium, South Bend, IN

James Ruckle, Ph.D., Secretary, President and CEO of Walther Cancer Foundation, Indianapolis, IN

Fuad Hammoudeh, Treasurer, Administrator of Cancer Programs at Clarian Health, Indianapolis, IN

Lawrence Einhorn, M.D., Chief Medical Officer, Distinguished Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Members At Large

Prasad Mantravadi, M.D., Principal Investigator for Radiation Oncology Associates, Evansville, IN

Patrick J. Loehrer, M.D., Interim Director and Medical Director at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Wael Harb, M.D., Principal Investigator of Horizon Oncology Center, Lafayette, IN

Naftali Bechar, M.D., Principal Investigator of Howard Regional Health Systems, Kokomo, IN

Clinical Trials Working Groups Co-Chairs

Breast

Kathy Miller, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Northern Indiana Cancer Research Consortium, South Bend, IN

Central Nervous System

Mark Henderson, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Charles Nock, M.D., University Hospital Case Medical Center, Cleveland, OH

Gastrointestinal

Gabi Chiorean, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Mary Mulcahy, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

Gynecology

Daniela Matei, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Greg Sutton, M.D., St. Vincent Oncology, Indianapolis, IN

Radiation

Achilles Fakiris, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Rao Prasad Mantravadi, M.D., Ft. Wayne Oncology & Hematology, Fort Wayne, IN

Genitourinary

Noah Hahn, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Guru Sonpavde, M.D., US Oncology, Texas

Hematology

Sheriff Farag, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Tamila Kindwall-Keller, M.D., University of Cleveland, OH

Head & Neck

Romnee Clark, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Daniel Weed, M.D., Clarian West Cancer Center, Indianapolis, IN

Supportive Care

Lawrence Einhorn, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Rudi Navari, M.D., University of Notre Dame, South Bend, IN

Thoracic

Nasser Hanna, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Jyoti Patel, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

New Partnerships and Collaborations

IU Circle of Life

The Hoosier Oncology Group partnered with the IU Circle of Life Indiana University Mini Marathon & 5k Run/Walk.

Over 45 Hoosier Oncology Group Road HOG Champions participated in the event on Saturday, April 4, 2009, on the beautiful IU Bloomington campus. We raised over \$10K for cancer research through the dedication and hard work of all Road HOG Champions.

“The Circle of Life, an Indiana University group responsible for planning the IU Mini Marathon, had the pleasure of partnering with Hoosier Oncology in 2009. (Hoosier Oncology Group’s) enthusiasm and energy was tangible. With its help, we were able to raise over \$35k that will go towards a scholarship endowment for cancer survivors. It was a pleasure to work with the entire team, and our event was far more successful because of our partnership.”

– **Matthew Berman**

Immediate Past Co-President and Chief Financial Officer,
IU Circle of Life Foundation



Purdue University, Discovery Park

One of the most exciting areas in cancer research today is in the field of proteomics and bioinformatics to identify new biomarkers for cancer diagnosis, progression and to monitor therapies.

Dr. Buck and his colleagues in Discovery Park utilize Hoosier Oncology Group's biorepository services for plasma proteomics studies.

"I am a cheerleader for the Hoosier Oncology Group because of the quality of the biospecimens and the information that accompanies these specimens. I know when I pull the samples out of my freezer, that these are high quality samples that are well-tracked, well-managed and information rich. Some researchers think biospecimens are too costly, but consistently high quality samples such as those collected by the Hoosier Oncology Group are invaluable."

— **Charles Buck, Ph.D.**
Director of Operations, Bindley
Bioscience Center in Discovery Park





Acknowledgements and Accolades

ASCO 2009

2009 follows the legacy of leadership, as Hoosier Oncology makes it 4 out of the last 5 years that our research outcomes have been featured as an oral presentation at the American Society of Clinical Oncology's annual meeting.

Oral Presentation

A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU04-75.

Poster Presentation

Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06-116.

Publication

Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern: HOG GI05-92.

Report of Independent Auditors

**To the Board of Directors
Hoosier Oncology Group, Inc.
Indianapolis, Indiana**

We have audited the accompanying statements of financial position of the Hoosier Oncology Group, Inc. (the "Organization") as of June 30, 2009 and 2008 and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Organization's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Hoosier Oncology Group, Inc. as of June 30, 2009 and 2008, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Our audits were made for the purpose of forming an opinion on the basic financial statements taken as a whole. The schedules of functional expenses are presented for purposes of additional analysis and are not a required part of the basic financial statements. Such information has been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, is fairly stated in all material respects in relation to the basic financial statements taken as a whole.

Crowe Horwath LLP
Indianapolis, Indiana
January 29, 2010

Hoosier Oncology Group, Inc.
 Statements of Financial Position
 June 30, 2009

	2009	2008
ASSETS		
Cash and cash equivalent	\$2,777,917	\$1,631,629
Accounts and grants receivable, net	915,276	1,015,850
Contributions receivable	—	2,217,251
Prepaid expenses	65,548	74,513
Property and equipment, net	69,181	140,841
Total assets	\$3,827,922	\$5,080,084
LIABILITIES and NET ASSETS		
Liabilities		
Accounts payable	\$278,953	\$341,365
Affiliate sites payable	117,562	621,531
Accrued payroll	42,364	39,818
Deferred revenue	225,388	285,118
Total liabilities	664,267	1,287,832
Net assets		
Unrestricted	3,041,155	3,669,752
Temporarily restricted	122,500	122,500
Total net assets	3,163,655	3,792,252
Total liabilities and net assets	\$3,827,922	\$5,080,084

Hoosier Oncology Group, Inc.
 Statements of Activities
 June 30, 2009

	Temporarily Unrestricted	2009 Restricted	2008 Total	Total
REVENUES				
External support - research	\$1,960,062	—	\$1,960,062	\$3,049,114
Federal research grants	406,683	—	406,683	97,317
Contributions and other grant support	80,587	—	80,587	4,011,356
Interest income	33,537	—	33,537	45,695
Other income	87,513	—	87,513	43,067
Total revenues	2,568,382	—	2,568,382	7,746,549
EXPENSES				
Program services				
Investigator initiated research	1,620,113	—	1,620,113	1,358,357
Industry research	369,022	—	369,022	766,731
Government research	599,903	—	599,903	670,360
Total program services	2,589,038	—	2,589,038	2,795,448
Supporting services				
Administration	495,735	—	495,735	1,052,656
Fundraising	112,206	—	112,206	106,193
Total supporting services	607,941	—	607,941	1,158,831
Total expenses	3,196,979	—	3,196,979	3,954,297
CHANGE IN NET ASSETS	(628,597)	—	(628,597)	3,792,252
Net assets, beginning of year	3,669,752	122,500	3,792,252	—
Net assets, end of year	\$3,041,155	\$122,500	\$3,163,655	\$3,792,252

Hoosier Oncology Group, Inc.
Statement of Cashflow from Operating Activities
June 30, 2009

	2009	2008
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$(628,597)	\$3,792,252
Adjustments to reconcile change in net assets to net cash used from operating activities:		
Depreciation	71,660	76,072
Provision for bad debts	–	70,879
Contribution of HOG LLC assets and liabilities:		
Accounts receivable	–	(1,496,161)
Fixed assets	–	(216,913)
Other assets	–	(55,353)
Accounts payable	–	1,151,131
Other liabilities	–	558,561
Change in assets and liabilities:		
Accounts and grants receivable	100,574	454,532
Contributions receivable	2,217,251	(2,217,251)
Prepaid expenses	8,965	(19,160)
Accounts payable	(62,412)	(854,866)
Affiliate sites payable	(503,969)	621,531
Accrued payroll	2,546	39,818
Deferred revenue	(59,730)	(273,443)
Net change in cash and cash equivalents	1,146,288	1,631,629
Cash and cash equivalents at beginning of year	1,631,629	–
Cash and cash equivalents at end of year	\$2,777,917	\$1,631,629
SUPPLEMENTARY DISCLOSURE		
Contributions of assets, net of liabilities from Walther Cancer Foundation	–	\$1,353,795

Thank You to Our Supporters

The Hoosier Oncology Group wishes to thank all those who contributed throughout the year to our mission of providing cutting-edge research to people within their community.

We are so fortunate to have many friends and supporters who give of their time, money, services, expertise and other valuable resources to help us fulfill our mission.

It is our hope that through their continued generosity, and through the generosity of others, that future generations may not know the pain of cancer.

Our Contributors*

PLATINUM (\$5000 and above)

Clarian Health
Dr. Nasser Hanna
Crowe Horwath LLP
Horizon Oncology Center
Michiana Hematology Oncology, PC
Union Hospital

SILVER (\$800 – \$2499)

Central Indiana Oncology Nursing Society
Dr. Lawrence Einhorn
Firestone Building Products
Fuad Hammoudeh
Heroes Foundation
Dr. Patrick Loehrer, Sr.
Dr. Mary Lou Mayer
Ted Stansbury
Dixie Weiss, In Memory of Jack Weiss

GOLD (\$2500 – \$4999)

Ice Miller, LLC
Oncology Hematology Associates of SW Indiana
Quake Pletcher
Paragon General Construction Company
Southern Roofing – Tracey Day

BRONZE (\$250 – \$799)

David Caldwell
Kristin Fenech
Kreg Gruber
Kevin Harvey
Dr. Kenneth Kesler
Jeffery LeCount
Dr. John McClean
Anne Merkel
Jennifer Nolan
Phillip Pletcher
Southern Roofing – Dave Tyndall
Elizabeth Simpson
Spring Creek Cattle Company
Barbara Stansbury
Duane Tyndall

FRIENDS (\$249 and under)

Tarick Abdo	Karen Gallagher-Horsting	Amanda Reed
Harold Anderson	Dan Gardner	Dan Rushing
Carol Anzalone	Susan Geggie	Don Russell
Joe Anzalone	Dr. Robert Goulet	Pat Russell
Janet Armstrong	Edward Gowens	Gregory Sandberg
Joanna Arnold	Louie Green	Sonal Sanghani
Suzanne Austin	Susan Haithcox	Ellen Saul
Al Baldwin	Andrea Hall	Stephanie Schoening
Troy Baughman	Jonathon Hardy	Bill & Wilma Schramm
Richard Bonebrake	Janet Harlan	Albert & Kevina Schumaker
Tom Borger	Lori Hedges	Ruth Ann Seaver
Carol Boyd	Brock Holst	Wilma Shafer
Kirk Bradley	Susan Hughes	Suzanne Short
Jan Broughton	Thelma Isgrigg	Brenda Sloan
Richard Burns	Jamar Johnson	Susan Stack
Donald Calvert	Timothy Judge	Cathi Steinacker
Stephen Calvert	Doug Keeslar	Teresa Swanson
Dr. Brian Clem	Jacqueline Kesler	Shad Tidler
Mary Cole	Paul Kilgore	Carol Tipton
Wade Cole	Pam Krengel	Jan Towner
Jeffrey Congdon	Cordelia Lewis	Thomas Ulbright
Julie Cooper	Stacey Loge	Kathleen Varera
Rich Correll	Jenny Lui	William Voelz
Annette Delaney	Charles Margolis	John Waffle
Cindy DeLeon-Ewing	Trina Martinez	Scott Waffle
Edwin Dermond	Lisa Meriweather	Thomas & Joann Walker
Judy DiAgostino	Mark Merryman	Cidney Walter
Douglas Dobson	Dr. David Moore	Jerry Walters
Leslie Donnelly	Karla Morton	James Weaver
Tim Dugle	Cheryl Motosicky	Peggy Weber
Suzanne Eger	Dr. Harikrishna Nakshatri	Earlita Webster
Jan Elrod	National Bank of Indianapolis	Dana Weiss
Matt Eppers	Tracey Odenwelder	Scott Welch
Leah Essex	Kelly O'Donnell	Gayla Williams
Dr. William Fisher	Stephen Parker	Ruth Workman
Michael Fisher	Susie Peebles	Betsy Yonker
Bill Flora	Shawna Ping	
George Furman	Jason Plassard	
David Gaglione	Antony Predan	

The Hoosier Oncology Group also wishes to thank all the dedicated investigators, clinical research site personnel and, most importantly, the patients who make our research possible.

*The Hoosier Oncology Group strives to acknowledge each and every contributor accurately. The information above reflects contributions made between July 1, 2008–June 30, 2009. If the information listed above is incorrect or not inclusive, please contact our offices at 317-921-2050 and ask for Cyndi Burkhardt. Thank you for your support!

Our Community Reach is Far and Wide

Our partnerships with the many academic and community cancer clinics across the United States enables oncologists to participate in meaningful cancer research while providing cutting-edge treatment to patients in their own communities.

ARKANSAS

Highlands Oncology Group, Fayetteville

DELAWARE

Helen F. Graham Cancer Center, Newark

FLORIDA

Shalk Cancer Center, University of Florida,
Gainesville

ILLINOIS

Ingalls Memorial Hospital, Harvey
Kellogg Cancer Care Center, Northshore Univ.
Health System, Evanston
Medical & Surgical Specialists, LLC, Galesburg
Northwestern University Feinberg School of
Medicine, Chicago
Rush-Presbyterian, Chicago
The University of Chicago, Chicago

INDIANA

Arnett Cancer Care, Lafayette
Cancer Care Center of S Indiana, Bloomington
Cancer Care Center, Inc., New Albany
Central Indiana Cancer Centers, Indianapolis
Community Cancer Care, Indianapolis
Community Regional Cancer Center, Indianapolis
Evansville Multi-Specialty Clinic, Evansville
Ft. Wayne Medical Oncology & Hem, Ft. Wayne
Good Samaritan Hospital, Vincennes
Center for Cancer Care at Goshen Health System,
Goshen
Horizon Oncology Center, Lafayette
IN Onc/Hem Consultants, Indianapolis
Indiana University Melvin and Bren Simon
Cancer Center, Indianapolis
Medical Center of Vincennes, Vincennes
Medical Consultants, P.C., Muncie
Medical Oncology/Hematology, Indianapolis
Monroe Medical Associates, Munster
Northern Indiana Cancer Research Consortium,
South Bend
Oncology Hematology Associates of SW Indiana,
Newburgh

Providence Medical Group, Terre Haute
South Bend Clinic, South Bend
St. Vincent Gynecologic Oncology, Indianapolis

LOUISIANA

Louisiana State University Health System,
Leonard J. Chabert Medical Center, Houma

MARYLAND

The Sidney Kimmel Cancer Center, John Hopkins,
Baltimore
University of Maryland, Baltimore

MASSACHUSETTS

Dana Farber Cancer Institute, Boston

MISSOURI

Washington University School of Medicine,
St. Louis

NEBRASKA

Methodist Cancer Center, Omaha
University of Nebraska Medical Center, Omaha

NEW JERSEY

(Fox Chase), Freehold
(Fox Chase), Hamilton
(Fox Chase), Howell
(Fox Chase), Lakewood
(Fox Chase), Manahawkin
(Fox Chase), Marmora
(Fox Chase), Mickleton
(Fox Chase), Mount Holly
(Fox Chase), Princeton
(Fox Chase), Redbank
(Fox Chase), Trenton
(Fox Chase), Vineland
(Fox Chase), Voorhees
Girish Amin (Fox Chase), Brick
Hem Onc Associates S.J., P.A., Mt. Holly
Myron Bednar (Fox Chase), Flemington

NEW YORK

Schwartz Gynecologic Oncology, PLLC,
Brightwaters

OHIO

University Hospitals of Cleveland, Ireland Cancer
Center, Cleveland

OREGON

Oregon Health and Science University, Portland
Providence Portland Medical Center, Portland

PENNSYLVANIA

(Fox Chase), Danville
(Fox Chase), Drexel Hill
(Fox Chase), Harrisburg
(Fox Chase), Langhorne
(Fox Chase), Paoli
(Fox Chase), Philadelphia
(Fox Chase), Pottstown
(Fox Chase), West Grove
(Fox Chase), West Reading
Consultants in Medical Oncology & Hematology,
Drexel Hill
Corey Langer (Fox Chase), Philadelphia
Pennsylvania Oncology Hematology Associates,
Philadelphia
Tony Magdalinski (Fox Chase), Sellersville
University of Pennsylvania, Philadelphia

SOUTH CAROLINA

Medical University of South Carolina, Charleston
Medical University of South Carolina, Spartanburg

TENNESSEE

The West Clinic (ACORN), Memphis

TEXAS

Baylor College of Medicine – Methodist Breast
Center, Houston
CTRRC at the UT Health Science Center
at San Antonio
The Methodist Hospital, Houston
Texas Oncology Cancer Center, Austin
US Oncology, Houston
University of Texas Southwestern Medical Center,
Dallas

VIRGINIA

Virginia Oncology Associates, Newport News

PERU

Instituto de Enfermedades Neoplásticas (INEN),
Lima

POLAND

Medical University of Gdansk (Poland), Gdansk

UNITED KINGDOM

St. Barts and The London School, London

351 W. 10th Street, Suite 330 • Indianapolis, IN 46202
www.hoosieroncologygroup.org